Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(06): 554-565
DOI: 10.1055/s-0043-1772203
Review Article

Monitoring Measurable/Minimal Residual Disease in Acute Myeloid Leukemia: Multiparametric Flow Cytometry-Based Approach

Prashant Ramesh Tembhare 
1   Hematopathology Laboratory, ACTREC, Tata Memorial Center, Homi Bhabha National Institute (HBNI) University, Maharashtra, India
› Author Affiliations Funding None declared.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Measurable/minimal residual disease (MRD) status is the most relevant predictor of clinical outcome in hematolymphoid neoplasms, including acute myeloid leukemia (AML). In contrast to acute lymphoblastic leukemia, multiple myeloma, or chronic lymphocytic leukemia, etc., AML is a widely heterogeneous neoplasm with poor clinical outcomes. Multicolor flow cytometry (MFC) is a powerful technology with high sensitivity, rapid results, cost-effectiveness, and easy availability. It is routinely used for diagnosing and MRD monitoring in many hematological neoplasms. However, MFC-based MRD monitoring in AML is complex and challenging. It requires a refined approach, a wide panel of markers, and adequate training and experience. This review focuses on the panel design, processing details, template design, analysis approach, and recent updates in MFC-based MRD monitoring in AML. It further describes the normal distribution and maturation patterns of various sublineages among hematological progenitors and their utility in studying AML MRD.

Keywords

flow cytometry - minimal residual disease - acute myeloid leukemia

Supplementary Material



Publication History

Article published online:
27 November 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373 (12) 1136-1152
    CrossrefPubMedSearch in Google Scholar
  • 2 Pessach I, Spyropoulos T, Lamprianidou E, Kotsianidis I. MRD monitoring by multiparametric flow cytometry in AML: is it time to incorporate immune parameters?. Cancers (Basel) 2022; 14 (17) 4294
    CrossrefPubMedSearch in Google Scholar
  • 3 Pratz KW, Jonas BA, Pullarkat V. et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022; 40 (08) 855-865
    CrossrefPubMedSearch in Google Scholar
  • 4 Rossi G, Giambra V, Minervini MM. et al. Leukemia-associated immunophenotypes subdivided in “categories of specificity” improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia. Cytometry B Clin Cytom 2020; 98 (03) 216-225
    CrossrefPubMedSearch in Google Scholar
  • 5 Khoury JD, Solary E, Abla O. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36 (07) 1703-1719
    CrossrefPubMedSearch in Google Scholar
  • 6 Cheson BD, Cassileth PA, Head DR. et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8 (05) 813-819
    CrossrefPubMedSearch in Google Scholar
  • 7 O'Donnell MR, Appelbaum F, Bishop M, Estey EH, Grever M, Maslak P. The National Comprehensive Cancer Network. NCCN acute leukemia practice guidelines. Oncology (Williston Park) 1996; 10 (11, Suppl): 205-221
    PubMedSearch in Google Scholar
  • 8 Appelbaum FR, Baer MR, Carabasi MH. et al; National Comprehensive Cancer Network. NCCN Practice Guidelines for acute myelogenous leukemia. Oncology (Williston Park) 2000; 14 (11A): 53-61
    PubMedSearch in Google Scholar
  • 9 Cheson BD, Bennett JM, Kopecky KJ. et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21 (24) 4642-4649
    CrossrefPubMedSearch in Google Scholar
  • 10 Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2004; 22 (16) 3432-3433
    CrossrefPubMedSearch in Google Scholar
  • 11 Inaba H, Coustan-Smith E, Cao X. et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012; 30 (29) 3625-3632
    CrossrefPubMedSearch in Google Scholar
  • 12 Loken MR, Alonzo TA, Pardo L. et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012; 120 (08) 1581-1588
    CrossrefPubMedSearch in Google Scholar
  • 13 Brodersen LE, Gerbing RB, Pardo ML. et al. Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report. Blood Adv 2020; 4 (20) 5050-5061
    CrossrefPubMedSearch in Google Scholar
  • 14 Chen X, Cherian S. Role of minimal residual disease testing in acute myeloid leukemia. Clin Lab Med 2021; 41 (03) 467-483
    CrossrefPubMedSearch in Google Scholar
  • 15 Shook D, Coustan-Smith E, Ribeiro RC, Rubnitz JE, Campana D. Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 2009; 9 (Suppl 3): S281-S285
    CrossrefPubMedSearch in Google Scholar
  • 16 Vedula RS, Lindsley RC. Measurement of residual disease in acute myeloid leukemia. Curr Hematol Malig Rep 2017; 12 (06) 574-581
    CrossrefPubMedSearch in Google Scholar
  • 17 Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008; 35 (04) 388-400
    CrossrefPubMedSearch in Google Scholar
  • 18 Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010; 22 (06) 656-663
    CrossrefPubMedSearch in Google Scholar
  • 19 Freeman SD, Virgo P, Couzens S. et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31 (32) 4123-4131
    CrossrefPubMedSearch in Google Scholar
  • 20 Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?. Blood 2014; 124 (23) 3345-3355
    CrossrefPubMedSearch in Google Scholar
  • 21 Buccisano F, Dillon R, Freeman SD, Venditti A. Role of minimal (measurable) residual disease assessment in older patients with acute myeloid leukemia. Cancers (Basel) 2018; 10 (07) 215
    CrossrefPubMedSearch in Google Scholar
  • 22 Freeman SD, Hills RK, Virgo P. et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol 2018; 36 (15) 1486-1497
    CrossrefPubMedSearch in Google Scholar
  • 23 Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia 2017; 31 (07) 1482-1490
    CrossrefPubMedSearch in Google Scholar
  • 24 Paterno G, Del Principe MI, Venditti A. Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?. Curr Opin Hematol 2020; 27 (02) 81-87
    CrossrefPubMedSearch in Google Scholar
  • 25 Schuurhuis GJ, Heuser M, Freeman S. et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131 (12) 1275-1291
    CrossrefPubMedSearch in Google Scholar
  • 26 DiNardo CD, Luger SM. Beyond morphology: minimal residual disease detection in acute myeloid leukemia. Curr Opin Hematol 2012; 19 (02) 82-88
    PubMedSearch in Google Scholar
  • 27 Jacobsohn DA, Loken MR, Fei M. et al. Outcomes of measurable residual disease in pediatric acute myeloid leukemia before and after hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. Biol Blood Marrow Transplant 2018; 24 (10) 2040-2046
    CrossrefPubMedSearch in Google Scholar
  • 28 Freeman SD, Hills RK, Russell NH. et al; UK NCRI AML Trial Group; HOVON AML Trial Group. Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults. Br J Haematol 2019; 186 (01) 130-133
    CrossrefPubMedSearch in Google Scholar
  • 29 Heuser M, Freeman SD, Ossenkoppele GJ. et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2021; 138 (26) 2753-2767
    CrossrefPubMedSearch in Google Scholar
  • 30 Chen X, Wood BL. Monitoring minimal residual disease in acute leukemia: technical challenges and interpretive complexities. Blood Rev 2017; 31 (02) 63-75
    CrossrefPubMedSearch in Google Scholar
  • 31 Thol F, Gabdoulline R, Liebich A. et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 2018; 132 (16) 1703-1713
    CrossrefPubMedSearch in Google Scholar
  • 32 Heuser M, Heida B, Büttner K. et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv 2021; 5 (09) 2294-2304
    CrossrefPubMedSearch in Google Scholar
  • 33 Simoes C, Paiva B, Martínez-Cuadrón D. et al. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Adv 2021; 5 (03) 760-770
    CrossrefPubMedSearch in Google Scholar
  • 34 Caballero-Velázquez T, Pérez-López O, Yeguas Bermejo A. et al. Prognostic value of measurable residual disease in patients with AML undergoing HSCT: a multicenter study. Cancers (Basel) 2023; 15 (05) 1609
    CrossrefPubMedSearch in Google Scholar
  • 35 Fuda F, Chen W. Minimal/measurable residual disease detection in acute leukemias by multiparameter flow cytometry. Curr Hematol Malig Rep 2018; 13 (06) 455-466
    CrossrefPubMedSearch in Google Scholar
  • 36 Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL. Deep NPM1 sequencing following allogeneic hematopoietic cell transplantation improves risk assessment in adults with NPM1-mutated AML. Biol Blood Marrow Transplant 2018; 24 (08) 1615-1620
    CrossrefPubMedSearch in Google Scholar
  • 37 Roloff GW, Lai C, Hourigan CS, Dillon LW. Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia. J Clin Med 2017; 6 (09) 87
    CrossrefPubMedSearch in Google Scholar
  • 38 Tettero JM, Freeman S, Buecklein V. et al. Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD working party. HemaSphere 2021; 6 (01) e676
    CrossrefPubMedSearch in Google Scholar
  • 39 Juul-Dam KL, Ommen HB, Nyvold CG. et al. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia. Br J Haematol 2020; 190 (02) 198-208
    CrossrefPubMedSearch in Google Scholar
  • 40 Zhang YW, Su L, Tan YH. et al. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia. Ann Hematol 2023; 102 (02) 337-347
    CrossrefPubMedSearch in Google Scholar
  • 41 McGowan F P, Hyter D S, Cui W, Plummer RM, Godwin AK, Zhang D. P FM. Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: one institute's practical clinical experience. Int J Lab Hematol 2022; 44 (01) 118-126
    CrossrefPubMedSearch in Google Scholar
  • 42 Patkar N, Kakirde C, Shaikh AF. et al. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia 2021; 35 (05) 1392-1404
    CrossrefPubMedSearch in Google Scholar
  • 43 Fajtova M, Babusikova O. Immunophenotype characterization of hematopoietic stem cells, progenitor cells restricted to myeloid lineage and their leukemia counterparts. Neoplasma 2010; 57 (05) 392-400
    CrossrefPubMedSearch in Google Scholar
  • 44 Pettit K, Stock W, Walter RB. Incorporating measurable (“minimal”) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma 2016; 57 (07) 1527-1533
    CrossrefPubMedSearch in Google Scholar
  • 45 Wouters R, Cucchi D, Kaspers GJ, Schuurhuis GJ, Cloos J. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design. Expert Rev Hematol 2014; 7 (06) 791-805
    CrossrefPubMedSearch in Google Scholar
  • 46 Farge T, Saland E, de Toni F. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov 2017; 7 (07) 716-735
    CrossrefPubMedSearch in Google Scholar
  • 47 Cloos J, Harris JR, Janssen JJWM. et al. Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia. J Vis Exp 2018; ;( (133) 56386
    PubMedSearch in Google Scholar
  • 48 Jaddaoui S, Bencharef H, Lamchahab M, Quessar A, Oukkache B. Prognostic impact and phenotype of residual acute myeloid leukemia stem cells. Clin Lab 2022;68(06):
  • 49 Khaldoyanidi SK, Hindoyan A, Stein A, Subklewe M. Leukemic stem cells as a target for eliminating acute myeloid leukemia: gaps in translational research. Crit Rev Oncol Hematol 2022; 175: 103710
    CrossrefPubMedSearch in Google Scholar
  • 50 Röhnert MA, Kramer M, Schadt J. et al. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. Leukemia 2022; 36 (09) 2208-2217
    CrossrefPubMedSearch in Google Scholar
  • 51 Kalina T, Flores-Montero J, van der Velden VH. et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26 (09) 1986-2010
    CrossrefPubMedSearch in Google Scholar
  • 52 Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010; 23 (03) 379-390
    CrossrefPubMedSearch in Google Scholar
  • 53 Baer MR, Stewart CC, Dodge RK. et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001; 97 (11) 3574-3580
    CrossrefPubMedSearch in Google Scholar
  • 54 Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T, Kern W. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004; 62 (01) 25-38
    CrossrefPubMedSearch in Google Scholar
  • 55 Zelezníková T, Babusíková O. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia. Neoplasma 2006; 53 (06) 500-506
    PubMedSearch in Google Scholar
  • 56 Langebrake C, Brinkmann I, Teigler-Schlegel A. et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. Cytometry B Clin Cytom 2005; 63 (01) 1-9
    CrossrefPubMedSearch in Google Scholar
  • 57 Xiao W, Petrova-Drus K, Roshal M. Optimal measurable residual disease testing for acute myeloid leukemia. Surg Pathol Clin 2019; 12 (03) 671-686
    CrossrefPubMedSearch in Google Scholar
  • 58 Wood BL. Acute myeloid leukemia minimal residual disease detection: the difference from normal approach. Curr Protoc Cytom 2020; 93 (01) e73
    CrossrefPubMedSearch in Google Scholar
  • 59 Wood BL. Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol 2013; 999: 123-136
    CrossrefPubMedSearch in Google Scholar
  • 60 Zhou Y, Wood BL. Methods of detection of measurable residual disease in AML. Curr Hematol Malig Rep 2017; 12 (06) 557-567
    CrossrefPubMedSearch in Google Scholar
  • 61 Bruserud Ø, Aasebø E, Hernandez-Valladares M, Tsykunova G, Reikvam H. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia: the biological background for possible strategies. Expert Opin Drug Discov 2017; 12 (10) 1053-1065
    CrossrefPubMedSearch in Google Scholar
  • 62 Canali A, Vergnolle I, Bertoli S. et al. Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia. Clin Cancer Res 2023; 29 (01) 134-142
    CrossrefPubMedSearch in Google Scholar
  • 63 Tembhare PR, Subramanian Pg Bertolli, Ghogale S. et al. A high-sensitivity 10-color flow cytometric minimal residual disease assay in B-lymphoblastic leukemia/lymphoma can easily achieve the sensitivity of 2-in-106 and is superior to standard minimal residual disease assay: a study of 622 patients. Cytometry B Clin Cytom 2020; 98 (01) 57-67
    CrossrefPubMedSearch in Google Scholar
  • 64 Tembhare PR, Chatterjee G, Khanka T. et al. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion. Cytometry B Clin Cytom 2021; 100 (04) 421-433
    CrossrefPubMedSearch in Google Scholar
  • 65 Aanei CM, Veyrat-Masson R, Selicean C. et al. Database-guided analysis for immunophenotypic diagnosis and follow-up of acute myeloid leukemia with recurrent genetic abnormalities. Front Oncol 2021; 11: 746951
    CrossrefPubMedSearch in Google Scholar
  • 66 Piñero P, Morillas M, Gutierrez N. et al. Identification of leukemia-associated immunophenotypes by databaseguided flow cytometry provides a highly sensitive and reproducible strategy for the study of measurable residual disease in acute myeloblastic leukemia. Cancers (Basel) 2022; 14 (16) 4010
    CrossrefPubMedSearch in Google Scholar
  • 67 Zeijlemaker W, Kelder A, Cloos J, Schuurhuis GJ. Immunophenotypic detection of measurable residual (stem cell) disease using LAIP approach in acute myeloid leukemia. Curr Protoc Cytom 2019; 91 (01) e66
    CrossrefPubMedSearch in Google Scholar
  • 68 Buccisano F, Palmieri R, Piciocchi A. et al. Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial. Haematologica 2022; 107 (12) 2823-2833
    CrossrefPubMedSearch in Google Scholar
  • 69 Paras G, Morsink LM, Othus M. et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood 2022; 139 (11) 1694-1706
    CrossrefPubMedSearch in Google Scholar
  • 70 Walter RB, Buckley SA, Pagel JM. et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013; 122 (10) 1813-1821
    CrossrefPubMedSearch in Google Scholar
  • 71 Norkin M, Katragadda L, Zou F. et al. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer J 2017; 7 (12) 634
    CrossrefPubMedSearch in Google Scholar
  • 72 Liu J, Ma R, Liu YR. et al. The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplant 2019; 54 (04) 567-577
    CrossrefPubMedSearch in Google Scholar
  • 73 Nagler A, Baron F, Labopin M. et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant 2021; 56 (01) 218-224
    CrossrefPubMedSearch in Google Scholar
  • 74 Fasan O. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia. Curr Opin Hematol 2019; 26 (06) 413-420
    CrossrefPubMedSearch in Google Scholar
  • 75 Guolo F, Di Grazia C, Minetto P. et al. Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. Eur J Haematol 2021; 107 (05) 573-582
    CrossrefPubMedSearch in Google Scholar
  • 76 Klyuchnikov E, Christopeit M, Badbaran A. et al. Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. Eur J Haematol 2021; 106 (05) 606-615
    CrossrefPubMedSearch in Google Scholar
  • 77 Oran B, Jorgensen JL, Marin D. et al. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 2017; 102 (01) 110-117
    CrossrefPubMedSearch in Google Scholar
  • 78 Shen X, Pan J, Qi C. et al. Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia. Hematology 2021; 26 (01) 295-300
    CrossrefPubMedSearch in Google Scholar
  • 79 Rossi G, Carella AM, Minervini MM. et al. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression. Leuk Res 2015; 39 (02) 138-143
    CrossrefPubMedSearch in Google Scholar
  • 80 Zhou Y, Othus M, Araki D. et al. Pre- and post-transplant quantification of measurable (“minimal”) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 2016; 30 (07) 1456-1464
    CrossrefPubMedSearch in Google Scholar
  • 81 Klyuchnikov E, Badbaran A, Massoud R. et al. Post-transplantation day +100 minimal residual disease detection rather than mixed chimerism predicts relapses after allogeneic stem cell transplantation for intermediate-risk acute myelogenous leukemia patients undergoing transplantation in complete remission. Transplant Cell Ther 2022; 28 (07) 374.e1-374.e9
    CrossrefPubMedSearch in Google Scholar
  • 82 Meur GL, Plesa A, Larcher MV. et al. Impact on outcome of minimal residual disease after hematopoietic stem cell transplantation with fludarabine, amsacrine, and cytosine arabinoside-busulfan conditioning: a retrospective monocentric study. Transplant Cell Ther 2023; 29 (01) 38.e1-38.e9
    CrossrefPubMedSearch in Google Scholar
  • 83 Winters AC, Bosma G, Abbott D. et al. Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy. Transplant Cell Ther 2022; 28 (10) 694.e1-694.e9
    CrossrefPubMedSearch in Google Scholar
  • 84 Soh KT, Conway A, Liu X, Wallace PK. Development of a 27-color panel for the detection of measurable residual disease in patients diagnosed with acute myeloid leukemia. Cytometry A 2022; 101 (11) 970-983
    CrossrefPubMedSearch in Google Scholar
  • 85 Maag AH, Swanton H, Kull M, Vegi NM, Feuring M. Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF). Cytometry A 2023; 1003 (07) 551-562
    CrossrefPubMedSearch in Google Scholar